AndreaBozzo/ceres-open-data-index huggingface dataset:
2020 Final Assisted Reproductive Technology (ART) Summary

ART data are made available as part of the National ART Surveillance System (NASS) that collects success rates, services, profiles and annual summary data from fertility clinics across the U.S. There are four datasets available: ART Services and Profiles, ART Patient and Cycle Characteristics, ART Success Rates, and ART Summary. All four datasets may be linked by “ClinicID.” ClinicID is a unique identifier for each clinic that reported cycles. The Summary dataset provides a full snapshot of clinic services and profile, patient characteristics, and ART success rates. It is worth noting that patient medical characteristics, such as age, diagnosis, and ovarian reserve, affect ART treatment’s success. Comparison of success rates across clinics may not be meaningful because of differences in patient populations and ART treatment methods. The success rates displayed in this dataset do not reflect any one patient’s chance of success. Patients should consult with a doctor to understand their chance of success based on their own characteristics.
2021 Final Assisted Reproductive Technology (ART) Patient and Cycle Characteristics

ART data are made available as part of the National ART Surveillance System (NASS) that collects success rates, services, profiles and annual summary data from fertility clinics across the U.S. There are four datasets available: ART Services and Profiles, ART Patient and Cycle Characteristics, ART Success Rates, and ART Summary. All four datasets may be linked by “ClinicID.” ClinicID is a unique identifier for each clinic that reported cycles. The Patient and Cycle Characteristics dataset summarizes the types of ART services performed and the kinds of patients who received ART procedures in a specific clinic. Please note patient characteristics are presented per cycle rather than per patient. As a result, patients who had more than one ART cycle within the reporting year are represented more than once.
2021 Final Assisted Reproductive Technology (ART) Services and Profiles

ART data are made available as part of the National ART Surveillance System (NASS) that collects success rates, services, profiles and annual summary data from fertility clinics across the U.S. There are four datasets available: ART Services and Profiles, ART Patient and Cycle Characteristics, ART Success Rates, and ART Summary. All four datasets may be linked by “ClinicID.” ClinicID is a unique identifier for each clinic that reported cycles. The Services and Profiles dataset provides an overview of clinic services, the clinic’s contact information, location, the medical director’s name, and summary statistics.
2021 Final Assisted Reproductive Technology (ART) Success Rates

Data were updated on September 11, 2024. ART data are made available as part of the National ART Surveillance System (NASS) that collects success rates, services, profiles and annual summary data from fertility clinics across the U.S. There are four datasets available: ART Services and Profiles, ART Patient and Cycle Characteristics, ART Success Rates, and ART Summary. All four datasets may be linked by “ClinicID.” ClinicID is a unique identifier for each clinic that reported cycles. The Success Rates dataset contains success rates for ART cycles started during the year indicated. Since ART success depends on whether patients are using their own eggs or donor eggs, success rates are included separately for these two groups. Success rates for patients using their own eggs are shown per intended retrieval, per actual retrieval, and per transfer. These success rates are reported as cumulative success rates, which take into account transfers that occur within 1 year after an egg retrieval. Since ART success depends on whether patients are using ART for the first time or had prior ART cycles, users can examine success rates for all “Patients using their own eggs” or for “Patients with no prior ART using their own eggs.” For new patients using ART for the first time, the success rates are also shown after 1, 2, or all intended egg retrievals during the reporting year. In addition, the average number of transfers per intended retrieval and the average number of intended retrievals per live-birth delivery are shown. Success rates for ART cycles that involve the transfer of embryos created from donor eggs or donated embryos are shown and are not cumulative. They are based on donor cycles started in the year indicated that had embryo transfers, regardless of when the donor eggs were retrieved. Success rates in this section are not presented by patient age group because previous data show that an intended parent’s age does not substantially affect success when using donor eggs or donated embryos. The success rates are presented by types of embryos and eggs used in the transfer. This dataset excludes cycles that were considered research—that is, cycles performed to evaluate new procedures.
2021 Final Assisted Reproductive Technology (ART) Summary

Data were updated on September 11, 2024. ART data are made available as part of the National ART Surveillance System (NASS) that collects success rates, services, profiles and annual summary data from fertility clinics across the U.S. There are four datasets available: ART Services and Profiles, ART Patient and Cycle Characteristics, ART Success Rates, and ART Summary. All four datasets may be linked by “ClinicID.” ClinicID is a unique identifier for each clinic that reported cycles. The Summary dataset provides a full snapshot of clinic services and profile, patient characteristics, and ART success rates. It is worth noting that patient medical characteristics, such as age, diagnosis, and ovarian reserve, affect ART treatment’s success. Comparison of success rates across clinics may not be meaningful because of differences in patient populations and ART treatment methods. The success rates displayed in this dataset do not reflect any one patient’s chance of success. Patients should consult with a doctor to understand their chance of success based on their own characteristics.
500 Cities: City-level Data (GIS Friendly Format), 2018 release

2016, 2015. Data were provided by the Centers for Disease Control and Prevention (CDC), Division of Population Health, Epidemiology and Surveillance Branch. The project was funded by the Robert Wood Johnson Foundation (RWJF) in conjunction with the CDC Foundation. 500 cities project city-level data in GIS-friendly format can be joined with city spatial data (https://chronicdata.cdc.gov/500-Cities/500-Cities-City-Boundaries/n44h-hy2j) in a geographic information system (GIS) to produce maps of 27 measures at the city-level. There are 4 measures (high blood pressure, taking high blood pressure medication, high cholesterol, cholesterol screening) in this 2018 release from the 2015 BRFSS that were the same as the 2017 release.
2022–2023 Nationwide Blood Donor Seroprevalence Survey Combined Infection- and Vaccination-Induced Seroprevalence Estimates

CDC is collaborating with Vitalant Research Institute, American Red Cross, and Westat Inc. to conduct a nationwide COVID-19 seroprevalence survey of blood donors. De-identified blood samples are tested for antibodies to SARS-CoV-2 to better understand the percentage of people in the United States who have antibodies against SARS-CoV-2 (the virus that causes COVID-19) and to track how this percentage changes over time. Both SARS-CoV-2 infection and COVID-19 vaccines currently used in the United States result in production of anti-spike (anti-S) antibodies but only infection results in production of anti-nucleocapsid (anti-N) antibodies. Infection-induced seroprevalence estimates the proportion of the population with antibody evidence of previous SARS-CoV-2 infection and refers to the percent of the population with anti-nucleocapsid antibodies. Combined infection-Induced and Vaccination-Induced seroprevalence estimates the proportion of the population with antibody evidence of previous SARS-CoV-2 infection, COVID-19 vaccination, or both, and refers to the percent of the population that has anti-spike antibodies, anti-nucleocapsid antibodies, or both. This link connects to a webpage that displays the data from the Nationwide Blood Donor Seroprevalence Survey. It offers an interactive visualization available at https://covid.cdc.gov/covid-data-tracker/#nationwide-blood-donor-seroprevalence-2022
2022 Final Assisted Reproductive Technology (ART) Patient and Cycle Characteristics

ART data are made available as part of the National ART Surveillance System (NASS) that collects success rates, services, profiles and annual summary data from fertility clinics across the U.S. There are four datasets available: ART Services and Profiles, ART Patient and Cycle Characteristics, ART Success Rates, and ART Summary. All four datasets may be linked by “ClinicID.” ClinicID is a unique identifier for each clinic that reported cycles. The Patient and Cycle Characteristics dataset summarizes the types of ART services performed and the kinds of patients who received ART procedures in a specific clinic. Please note patient characteristics are presented per cycle rather than per patient. As a result, patients who had more than one ART cycle within the reporting year are represented more than once.
2022 Final Assisted Reproductive Technology (ART) Services and Profiles

ART data are made available as part of the National ART Surveillance System (NASS) that collects success rates, services, profiles and annual summary data from fertility clinics across the U.S. There are four datasets available: ART Services and Profiles, ART Patient and Cycle Characteristics, ART Success Rates, and ART Summary. All four datasets may be linked by “ClinicID.” ClinicID is a unique identifier for each clinic that reported cycles. The Services and Profiles dataset provides an overview of clinic services, the clinic’s contact information, location, the medical director’s name, and summary statistics.
2022 Final Assisted Reproductive Technology (ART) Success Rates

ART data are made available as part of the National ART Surveillance System (NASS) that collects success rates, services, profiles and annual summary data from fertility clinics across the U.S. There are four datasets available: ART Services and Profiles, ART Patient and Cycle Characteristics, ART Success Rates, and ART Summary. All four datasets may be linked by “ClinicID.” ClinicID is a unique identifier for each clinic that reported cycles. The Success Rates dataset contains success rates for ART cycles started during the year indicated. Since ART success depends on whether patients are using their own eggs or donor eggs, success rates are included separately for these two groups. Success rates for patients using their own eggs are shown per intended retrieval, per actual retrieval, and per transfer. These success rates are reported as cumulative success rates, which take into account transfers that occur within 1 year after an egg retrieval. Since ART success depends on whether patients are using ART for the first time or had prior ART cycles, users can examine success rates for all “Patients using their own eggs” or for “Patients with no prior ART using their own eggs.” For new patients using ART for the first time, the success rates are also shown after 1, 2, or all intended egg retrievals during the reporting year. In addition, the average number of transfers per intended retrieval and the average number of intended retrievals per live-birth delivery are shown. Success rates for ART cycles that involve the transfer of embryos created from donor eggs or donated embryos are shown and are not cumulative. They are based on donor cycles started in the year indicated that had embryo transfers, regardless of when the donor eggs were retrieved. Success rates in this section are not presented by patient age group because previous data show that an intended parent’s age does not substantially affect success when using donor eggs or donated embryos. The success rates are presented by types of embryos and eggs used in the transfer. This dataset excludes cycles that were considered research—that is, cycles performed to evaluate new procedures.
2022 Final Assisted Reproductive Technology (ART) Summary

ART data are made available as part of the National ART Surveillance System (NASS) that collects success rates, services, profiles and annual summary data from fertility clinics across the U.S. There are four datasets available: ART Services and Profiles, ART Patient and Cycle Characteristics, ART Success Rates, and ART Summary. All four datasets may be linked by “ClinicID.” ClinicID is a unique identifier for each clinic that reported cycles. The Summary dataset provides a full snapshot of clinic services and profile, patient characteristics, and ART success rates. It is worth noting that patient medical characteristics, such as age, diagnosis, and ovarian reserve, affect ART treatment’s success. Comparison of success rates across clinics may not be meaningful because of differences in patient populations and ART treatment methods. The success rates displayed in this dataset do not reflect any one patient’s chance of success. Patients should consult with a doctor to understand their chance of success based on their own characteristics.
Access and Use of Telemedicine During COVID-19

The Research and Development Survey (RANDS) is a platform designed for conducting survey question evaluation and statistical research. RANDS is an ongoing series of surveys from probability-sampled commercial survey panels used for methodological research at the National Center for Health Statistics (NCHS). RANDS estimates are generated using an experimental approach that differs from the survey design approaches generally used by NCHS, including possible biases from different response patterns and sampling frames as well as increased variability from lower sample sizes. Use of the RANDS platform allows NCHS to produce more timely data than would be possible using traditional data collection methods. RANDS is not designed to replace NCHS’ higher quality, core data collections. Below are experimental estimates of telemedicine access and use for three rounds of RANDS during COVID-19. Data collection for the three rounds of RANDS during COVID-19 occurred between June 9, 2020 and July 6, 2020, August 3, 2020 and August 20, 2020, and May 17, 2021 and June 30, 2021. Information needed to interpret these estimates can be found in the Technical Notes. RANDS during COVID-19 included questions about whether providers offered telemedicine (including video and telephone appointments) in the last 2 months—both during and before the pandemic—and about the use of telemedicine in the last 2 months during the pandemic. As a result of the coronavirus pandemic, many local and state governments discouraged people from leaving their homes for nonessential reasons. Although health care is considered an essential activity, telemedicine offers an opportunity for care without the potential or perceived risks of leaving the home. The National Health Interview Survey, conducted by NCHS, added telemedicine questions to its sample adult questionnaire in July 2020. The Household Pulse Survey (https://www.cdc.gov/nchs/covid19/pulse/telemedicine-use.htm), an online survey conducted in response to the COVID-19 pandemic by the Census Bureau in partnership with other federal agencies including NCHS, also reports estimates of telemedicine use during the pandemic (beginning in Phase 3.1, which started on April 14, 2021). The Household Pulse Survey reports telemedicine use in the last 4 weeks among adults and among households with at least one child under age 18 years. The experimental estimates on this page are derived from RANDS during COVID-19 and show the percentage of U.S. adults who have a usual place of care and a provider that offered telemedicine in the past 2 months, who used telemedicine in the past 2 months, or who have a usual place of care and a provider that offered telemedicine prior to the coronavirus pandemic. Technical Notes: https://www.cdc.gov/nchs/covid19/rands/telemedicine.htm#limitations
2023 Respiratory Virus Response - NSSP Emergency Department Visit Trajectories by State- COVID-19, Flu, RSV, Combined

2023 Respiratory Viruses Response – National Syndromic Surveillance Program Emergency Department Visit Trajectories - COVID-19, Flu, RSV, Combined – by state. This dataset provides the percentage of emergency department patient visits for the specified pathogen of all ED patient visits for the specified geography that were observed for the given week from data submitted to the National Syndromic Surveillance Program (NSSP). In addition, the trend over time both as of the given row date and as of the most current data submitted is characterized as increasing, decreasing or stable to provide awareness of how the weekly trend is changing for the given geographic region. For the emergency department time series, trajectory classifications reported on the opening page are based on rolling regression model assessments of the slope for each respiratory illness. Weeks with a significant time term (p <0.05) are classified as increasing when the slope is positive and decreasing when the slope is negative. Weeks with a non-significant time term (p ≥ 0.05) are classified as stable. A 3-week moving average is applied to the time series prior to the regression procedure in order to smooth week-to-week variation. For additional information, please see:[Companion Guide: NSSP Emergency Department Data on Respiratory Illness] Updated once per week on Fridays.
500 Cities: Census Tract-level Data (GIS Friendly Format), 2016 release

2014, 2013. Data were provided by the Centers for Disease Control and Prevention (CDC), Division of Population Health, Epidemiology and Surveillance Branch. The project was funded by the Robert Wood Johnson Foundation (RWJF) in conjunction with the CDC Foundation. 500 cities project census tract-level data in GIS-friendly format can be joined with census tract spatial data (https://chronicdata.cdc.gov/500-Cities/500-Cities-Census-Tract-Boundaries/x7zy-2xmx) in a geographic information system (GIS) to produce maps of 27 measures at the census tract level.
500 Cities: Census Tract-level Data (GIS Friendly Format), 2017 release

2015, 2014. Data were provided by the Centers for Disease Control and Prevention (CDC), Division of Population Health, Epidemiology and Surveillance Branch. The project was funded by the Robert Wood Johnson Foundation (RWJF) in conjunction with the CDC Foundation. 500 cities project census tract-level data in GIS-friendly format can be joined with census tract spatial data (https://chronicdata.cdc.gov/500-Cities/500-Cities-Census-Tract-Boundaries/x7zy-2xmx) in a geographic information system (GIS) to produce maps of 27 measures at the census tract level. Because some questions are only asked every other year in the BRFSS, there are 7 measures in this 2017 release from the 2014 BRFSS that were the same as the 2016 release.
500 Cities: Census Tract-level Data (GIS Friendly Format), 2018 release

2016, 2015. Data were provided by the Centers for Disease Control and Prevention (CDC), Division of Population Health, Epidemiology and Surveillance Branch. The project was funded by the Robert Wood Johnson Foundation (RWJF) in conjunction with the CDC Foundation. 500 cities project census tract-level data in GIS-friendly format can be joined with census tract spatial data (https://chronicdata.cdc.gov/500-Cities/500-Cities-Census-Tract-Boundaries/x7zy-2xmx) in a geographic information system (GIS) to produce maps of 27 measures at the census tract level. There are 4 measures (high blood pressure, taking high blood pressure medication, high cholesterol, cholesterol screening) in this 2018 release from the 2015 BRFSS that were the same as the 2017 release.
500 Cities: Census Tract-level Data (GIS Friendly Format), 2019 release

2017, 2016. Data were provided by the Centers for Disease Control and Prevention (CDC), Division of Population Health, Epidemiology and Surveillance Branch. The project was funded by the Robert Wood Johnson Foundation (RWJF) in conjunction with the CDC Foundation. 500 cities project census tract-level data in GIS-friendly format can be joined with census tract spatial data (https://chronicdata.cdc.gov/500-Cities/500-Cities-Census-Tract-Boundaries/x7zy-2xmx) in a geographic information system (GIS) to produce maps of 27 measures at the census tract level. There are 7 measures (all teeth lost, dental visits, mammograms, Pap tests, colorectal cancer screening, core preventive services among older adults, and sleep less than 7 hours) in this 2019 release from the 2016 BRFSS that were the same as the 2018 release.
500 Cities: City-level Data (GIS Friendly Format), 2016 release

2014, 2013. Data were provided by the Centers for Disease Control and Prevention (CDC), Division of Population Health, Epidemiology and Surveillance Branch. The project was funded by the Robert Wood Johnson Foundation (RWJF) in conjunction with the CDC Foundation. 500 cities project census city-level data in GIS-friendly format can be joined with city spatial data (https://chronicdata.cdc.gov/500-Cities/500-Cities-City-Boundaries/n44h-hy2j) in a geographic information system (GIS) to produce maps of 27 measures at the city-level.
500 Cities: City-level Data (GIS Friendly Format), 2019 release

2017, 2016. Data were provided by the Centers for Disease Control and Prevention (CDC), Division of Population Health, Epidemiology and Surveillance Branch. The project was funded by the Robert Wood Johnson Foundation (RWJF) in conjunction with the CDC Foundation. 500 cities project city-level data in GIS-friendly format can be joined with city spatial data (https://chronicdata.cdc.gov/500-Cities/500-Cities-City-Boundaries/n44h-hy2j) in a geographic information system (GIS) to produce maps of 27 measures at the city-level. There are 7 measures (all teeth lost, dental visits, mammograms, Pap tests, colorectal cancer screening, core preventive services among older adults, and sleep less than 7 hours) in this 2019 release from the 2016 BRFSS that were the same as the 2018 release.